TriSalus Life Sciences
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Employees
- 112
- Market Cap
- -
- Website
- https://trisaluslifesci.com
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05607953
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- Conditions
- Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05220722
- Locations
- πΊπΈ
University of Colorado, Aurora, Colorado, United States
πΊπΈColumbia University, New York, New York, United States
πΊπΈRhode Island Hospital, Providence, Rhode Island, United States
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma in the Liver
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04935229
- Locations
- πΊπΈ
UCLA, Los Angeles, California, United States
πΊπΈStanford, Stanford, California, United States
πΊπΈUniversity of Colorado, Denver, Colorado, United States
News
TriSalus Launches Enhanced TriNav FLX Infusion System for Improved Tumor Drug Delivery
TriSalus Life Sciences has launched the TriNav FLX Infusion System, featuring enhanced trackability with twice the length of flexible material at the distal end for easier navigation through tortuous vessels.
TriSalus Life Sciences Secures $22 Million Private Placement to Advance Oncology Drug Delivery Platform
TriSalus Life Sciences raised $22 million in a private placement led by Nantahala Capital and Broadfin Holdings to accelerate its oncology drug delivery technology applications.
TriSalus Life Sciences' TriNav System Enhances Liver Tumor Embolic Microsphere Delivery
TriSalus Life Sciences reports that its TriNav Infusion System, using Pressure Enabled Drug Delivery (PEDD), significantly improves the delivery of Embospheres to liver tumors in preclinical models.